Tingsheng Technology

About Tingsheng Technology

Jiangsu Tingsheng Technology Co., Ltd. operates at the forefront of the medical device sector, specifically focusing on ultrasound technology for cardiac applications. Founded in November 2017 by Chairman Zhang Dongyu and General Manager Wang Jing, who assembled a team of ultrasound scientists, cardiologists, and entrepreneurs, the company aims to address the high costs and foreign market dominance in cardiac interventional therapies. Headquartered in Nanjing, China, with an R&D center in Massachusetts, USA, Tingsheng Technology has established a significant footprint with a nearly 4,800-square-meter R&D and manufacturing center.

The company's business revolves around the development, production, and sale of Class III cardiac interventional medical devices. Its revenue model is based on selling these advanced medical products to healthcare institutions. Tingsheng's core offering is its Intracardiac Echocardiography (ICE) system, which includes single-use catheters and portable ultrasound diagnostic devices. A key milestone was achieved in November 2023, when its 'Disposable Intracardiac Ultrasound Diagnostic Catheter' (TINGSN Sonic Eyes 10) received NMPA approval, becoming the first domestically developed product of its kind in China and breaking the existing foreign monopoly. This product provides real-time, precise anatomical images from within the heart, serving as the 'eyes' for surgeons during interventional procedures for conditions like structural heart disease and cardiac arrhythmias.

The company is actively developing next-generation products, including a 4D ICE system, which has already undergone its first human clinical study, and systems for ultrasonic 3D mapping and ultrasound-based energy ablation. This strategic focus on advanced R&D is backed by substantial investment, including multiple financing rounds from prominent investors such as Qiming Venture Partners, Yifeng Capital, and京铭资本. This positions Tingsheng Technology to enhance its market competitiveness globally and make advanced cardiac care more accessible and affordable.